Modulators of alpha-1 antitrypsin

US11623924B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Upul K. Bandarage · Lexington, US
• Cavan McKeon Bligh · Somerville, US
• Michael Boyd · Winchester, US
• Diane Boucher · Boston, US
• Michael Aaron Brodney · East Lyme, US
• Veronique Damagnez · Cambridge, US
• Lev Tyler DEWEY FANNING · San Marcos, US
• Mary Elizabeth ECCLES · Cambridge, US
• Robert Francis Fimognari · Brookline, US
• Kevin James GAGNON · Acton, US
• Pedro Manuel GARCIA BARRANTES · Melrose, US
• Simon Giroux · Cambridge, US
• Ronald Grey, Jr. · Mansfield, US
• Amy Beth HALL · Wellesley, US
• Sarah Carol HOOD · Worcester, US
• Dennis James Hurley · San Marcos, US
• Joshua Kennedy HUSSEY · Pepperell, US
• Mac Arthur Johnson, Jr. · Derry, US
• Peter Jones · Sharon, US
• Sarathy KESAVAN · Quincy, US
• Adam Looker · Newton, US
• Brad D. Maxwell · Holliston, US
• John Patrick Maxwell · Hingham, US
• Ales Medek · Winchester, US
• Mettachit Navamal · Belmont, US
• Philippe Marcel Nuhant · Milton Village, US
• Setu Roday · Arlington, US
• Stefanie Roeper · Medford, US
• Rupa SAWANT · Wayland, US
• Yi-Qun Shi · East Brunswick Township, US

Key dates

• Filing date: Oct 4, 2019
• Grant date: Apr 11, 2023
• Expiry date: Oct 4, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).